8-K: STAAR Surgical Reports Strong 2023 Results and Affirms 2024 Outlook

STAAR Surgical reported strong net sales, cash generation, and profitability for 2023, with global ICL unit growth exceeding refractive industry growth by over 25 points.

Summary

• STAAR Surgical reported a 22% increase in ICL sales for the fourth quarter of 2023 and an 18% increase for the full year.
• The company's APAC and EMEA regions drove ICL sales growth in the quarter, with China, Japan, South Korea, and Germany showing standout growth.
• STAAR's US sales were approximately $4.2 million for the fourth quarter, flat sequentially.
• The company has a record $232 million in cash and investments as of year-end.
• STAAR is affirming its net sales outlook for fiscal year 2024 of $335 million to $340 million.
• The company expects adjusted EBITDA for fiscal year 2024 to be approximately $36 million, or 10.5% of net sales.
• Gross profit for Q4 2023 was $60.7 million, or 79.6% of net sales.
• The company expects gross margin to be approximately 80% for each quarter and the full year of 2024.
• STAAR is investing in manufacturing capacity expansion, information technology, and support with $30 million in property and equipment investments expected for fiscal 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment with strong financial results, growth in key markets, and a clear strategic plan. The company is also investing in future growth and innovation. There are some risks and challenges, but the overall tone is optimistic.

Positives

• STAAR's business model is growing profitably with high gross margins and the ability to drive higher operating margins.
• The company has a strong financial position with a record $232 million in cash and investments.
• The number of patients with myopia, which their technology treats, is expected to reach $5 billion by 2050.
• The company is expanding its infrastructure in China with a second large distributor and more in-country employees.
• The US Highway 93 go-to-market initiative is showing progress with a strategic agreement with SharpeVision.
• STAAR is launching similar initiatives in key European markets using the Highway 93 model.
• The company is increasing surgeon confidence in measurement of the eye and lens selection with upcoming publications and AI-based tools.
• STAAR is moving down the diopter curve to lower levels of vision correction, initially targeting minus six to minus eight diopters.
• The company is innovating with new products and solutions, including a new surgeon-loaded injector and the Stella ICL ordering system.
• The company is introducing a new profitability metric, adjusted EBITDA, to better represent the underlying performance of the business.

Negatives

• US sales were flat sequentially in Q4 2023.
• The company expects flat growth across all geographies except China and the US, primarily due to the dynamic macroeconomic environment.
• GAAP operating income for fiscal 2023 was $28.1 million, down from $43.8 million in fiscal 2022.
• The company is increasing G&A expenses in 2024 to invest in back-office infrastructure and scalability.

Risks

• The company's forward-looking statements are subject to numerous important risks and uncertainties that could cause actual results to differ materially.
• The macroeconomic environment could impact growth rates in various regions.
• The company faces competition in the ICL market, particularly in China.
• The company's success depends on increasing surgeon confidence and adoption of its technology.
• The company's ability to achieve its Vision 2026 goals depends on successful execution of its growth initiatives.

Future Outlook

STAAR Surgical affirms its net sales outlook for fiscal year 2024 of $335 million to $340 million and believes the path towards its Vision 2026 three-year CAGR of 15% to 20% remains intact. The company anticipates higher growth rates in the second half of 2024.

Management Comments

• Tom Frinzi stated that STAAR's business model is rare to find, growing profitably with high gross margins and the ability to continue to drive higher operating margins.
• Tom Frinzi mentioned that the company is investing in people and infrastructure in China to realize the growing opportunity.
• Tom Frinzi noted that the US remains an important growth opportunity for STAAR and that the Highway 93 initiative is beginning to show progress.
• Patrick Williams stated that the company values itself as a growth company and is heavily investing in the commercial organization.
• Patrick Williams mentioned that the company is changing its marketing strategy to focus more on co-marketing with practices at the ground level.

Industry Context

The announcement highlights STAAR Surgical's continued growth in the refractive surgery market, particularly with its ICL technology. The company is expanding its reach in key markets like China and the US, while also focusing on innovation and surgeon education. The company is also addressing the trend of declining refractive surgery volumes by focusing on lens-based solutions.

Comparison to Industry Standards

• STAAR's ICL unit growth exceeded the refractive industry growth by over 25 points, indicating a strong market position compared to competitors.
• The company's focus on lens-based refractive surgery positions it well against traditional laser vision correction methods, which are experiencing a deceleration in growth.
• The company's expansion in China, with the addition of a second distributor, is a strategic move to capture a larger share of the growing market, similar to other medical device companies expanding in the region.
• The company's gross margin of approximately 80% is a strong indicator of profitability and efficiency, comparable to other successful medical device companies.
• The company's investment in R&D and new product development, such as the EVO+ lens and AI-based lens selection tools, demonstrates a commitment to innovation, similar to other leading companies in the medical technology sector.

Stakeholder Impact

• Shareholders will benefit from the company's strong financial performance and growth prospects.
• Employees will benefit from the company's investment in infrastructure and expansion.
• Customers (surgeons and patients) will benefit from the company's focus on innovation and improved technology.
• Suppliers will benefit from the company's increased manufacturing capacity.
• Creditors will benefit from the company's strong cash position.

Next Steps

• STAAR will participate in the Jefferies West Coast Bus Tour, the Oppenheimer Healthcare Conference, and the Sidoti Small Cap Conference.
• The company will participate in in-person investor meetings in China in the cities of Shanghai and Shenzhen.
• STAAR expects to report its first-quarter results in early May.

Key Dates

Keywords

ICL, refractive surgery, myopia, EVO ICL, China, APAC, EMEA, US, lens-based technology, adjusted EBITDA